Inositol hexaphosphate hydrolysate competitively binds to AKT to inhibit the proliferation of colon carcinoma.
Phytate, myto-inositol 1,2,3,4,5,6 hexaphosphate (IP6), is recognized as an anti-nutrition phytochemical for decades. Recently, numerous studies have indicated that IP6 and its hydrolysates could suppress colon oncogenesis. However, very little is known concerning the mechanism of IP6 hydrolysates in regulating colon oncogenesis. The aim of the present study was to identify the underlying relationship between IP6 hydrolysates and colon cancer. Three types of human colorectal cancer cells were utilized in the present study. The proliferation inhibition and migration assays were employed to reveal that IP6 hydrolysates inhibited the proliferation of SW620 cells. Real-time PCR, cell-based ELISA and the AKT inhibitor assay were utilized to reveal that 20 and 30% degree of hydrolysis hydrolysates of IP6 inhibited SW620 cell growth by inhibiting the activation of AKT protein. The docking simulation study revealed that IP4 and IP5 could inhibit the activation of AKT by binding to PIP3 receptor. Collectively, our results indicated that the IP6 hydrolysates inhibit SW620 cell proliferation; IP4 and IP5, the probable primary constituents of the 20-30% degree of hydrolysis hydrolysates of IP6, inhibited the proliferation of SW620 cells by competitively inhibiting the AKT protein.